 | Up a level |
2021
Reimann, Maurice, Schrezenmeier, Jens, Richter-Pechanska, Paulina, Dolnik, Anna, Hick, Timon Pablo, Schleich, Kolja, Cai, Xiurong, Fan, Dorothy N. Y., Lohneis, Philipp, Masswig, Sven, Denker, Sophy 
ORCID: 0000-0002-0736-6019, Busse, Antonia ORCID: 0000-0002-3470-6947, Knittel, Gero ORCID: 0000-0001-8395-3701, Flumann, Ruth, Childs, Dorothee, Childs, Liam ORCID: 0000-0002-2080-1804, Gaetjens-Sanchez, Ana-Maria, Bullinger, Lars ORCID: 0000-0002-5890-5510, Rosenwald, Andreas, Reinhardt, Hans Christian and Schmitt, Clemens A. ORCID: 0000-0002-4731-2226
(2021).
Adaptive T-cell immunity controls senescence-prone MyD88-or CARD11-mutant B-cell lymphomas.
Blood, 137 (20).
S. 2785 - 2800.
WASHINGTON:
AMER SOC HEMATOLOGY.
ISSN 1528-0020
2020
Edelmann, Jennifer, Holzmann, Karlheinz, Tausch, Eugen, Saunderson, Emily A., Jebaraj, Billy M. C., Steinbrecher, Daniela, Dolnik, Anna, Blaette, Tamara J., Landau, Dan A., Saub, Jenny, Estenfelder, Sven, Ibach, Stefan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain ORCID: 0000-0002-1430-2574, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Goede, Valentin, Bullinger, Lars, Wu, Catherine J., Mertens, Daniel ORCID: 0000-0003-0227-7188, Ficz, Gabriella, Gribben, John G., Hallek, Michael, Doehner, Hartmut and Stilgenbauer, Stephan
(2020).
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription.
Haematologica, 105 (5).
S. 1379 - 1391.
PAVIA:
FERRATA STORTI FOUNDATION.
ISSN 0390-6078
Tausch, Eugen, Schneider, Christof, Robrecht, Sandra, Zhang, Can, Dolnik, Anna, Bloehdorn, Johannes, Bahlo, Jasmin, Al-Sawaf, Othman, Ritgen, Matthias, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Tandon, Maneesh, Humphrey, Kathryn, Jiang, Yanwen, Schary, William, Bullinger, Lars, Mertens, Daniel, Lura, Michele Porro, Kneba, Michael, Doehner, Hartmut, Fischer, Kirsten, Hallek, Michael and Stilgenbauer, Stephan (2020). Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood, 135 (26). S. 2402 - 2413. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020